255 related articles for article (PubMed ID: 28188628)
1. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP
J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300
[TBL] [Abstract][Full Text] [Related]
5. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
6. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
7. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Jaber SH; Cowen EW; Haworth LR; Booher SL; Berman DM; Rosenberg SA; Hwang ST
Arch Dermatol; 2006 Feb; 142(2):166-72. PubMed ID: 16490844
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
9. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
[TBL] [Abstract][Full Text] [Related]
16. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
[TBL] [Abstract][Full Text] [Related]
17. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
20. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
Sundaresan S; Nguyen KT; Nelson KC; Ivan D; Patel AB
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
